Roth Capital Reiterates Buy On Iradimed Shares, $12 PT


In a research report issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Iradimed Corp (NASDAQ:IRMD) with a price target of $12.00.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chris Lewis has a total average return of -6.8% and a 45.2% success rate. Lewis has a 4.5% average return when recommending IRMD, and is ranked #3144 out of 3349 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts